1.1Antibody delivery of a cytotoxin
The antibody binds an extracellular receptor on the tumor cell, and the cell internalizes the complex. Lysosomal proteases cleave the linker and release the inhibitor, which disrupts microtubule assembly.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The antibody binds an extracellular receptor on the tumor cell, and the cell internalizes the complex. Lysosomal proteases cleave the linker and release the inhibitor, which disrupts microtubule assembly.
The furan shares two adjacent carbon atoms with a benzene ring to form a planar benzofuran core. Substituents on the fused system project from its perimeter, and the furan oxygen supplies a hydrogen-bond acceptor.
A two-carbon chain joins the core carbon at X to a terminal dimethylamino group. Protonation at the tertiary amine creates a water-soluble salt form for aqueous formulation.
The nitrile carbon bonds directly to the W1 ring carbon through a single bond. The carbon–nitrogen triple bond gives the substituent a linear shape and places a hydrogen-bond acceptor at its tip.
A two-carbon chain attaches to the W2 ring carbon and terminates in a primary alcohol. The terminal hydroxyl donates and accepts hydrogen bonds and increases hydration at the end of the chain.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
W1 is a pyridine-type nitrogen bonded to the two adjacent atoms of the aromatic ring. Its lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.
W2 is an aromatic carbon bonded to one hydrogen and to its two ring neighbors. Its perpendicular p orbital participates in the conjugated ring system.
RW2 is a fluorine atom bonded directly to the aromatic carbon at W2. The polarized carbon–fluorine bond changes the local electron distribution at that position.
RW3 is a two-carbon ethynyl group attached through one of its triple-bonded carbons to the W3 ring carbon. The distal carbon bears a hydrogen, and the triple bond holds the substituent along a linear axis.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The methods for treating microbial infections comprise administering to a subject in need thereof an active compound as described herein. These active compounds, as set forth above, include compounds of Formula (I-V), their corresponding prodrugs, and pharmaceutically acceptable salts of the compounds and prodrugs.A · US 2006/0293328 A1 · ¶ 266
A method of treating cancer in a mammal, comprising administering to said mammal an effective amount of a compound of formula (VI): or a pharmacologically acceptable salt thereof, wherein: R4, R5, R7 and R8 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substB · US 10,080,739 B2 · claim 1
Ar1 and Ar3 are independently selected from the group consisting of: wherein: A, Y, and Z are independently selected from the group consisting of N and CR4, and wherein R4 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl;A · US 2006/0293328 A1 · claim 37
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkylB · US 10,080,739 B2 · claim 1
Alkyl groups can optionally be substituted (a “substituted alkyl”) with one or more alkyl group substituents, which can be the same or different. The term “alkyl group substituent” includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.A · US 2006/0293328 A1 · ¶ 91
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkylB · US 10,080,739 B2 · claim 1
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkylB · US 10,080,739 B2 · claim 1
Alkyl groups can optionally be substituted (a “substituted alkyl”) with one or more alkyl group substituents, which can be the same or different. The term “alkyl group substituent” includes but is not limited to alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl.A · US 2006/0293328 A1 · ¶ 91
R11, R12, R14, R15, R16, and R18 are independently hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkylalkynyl, alkoxy, alkylthio, acyl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, substituted heteroaryl, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkylB · US 10,080,739 B2 · claim 1
Ar2 is selected from the group consisting of: wherein: A1, A2, A3, Y1, Y2, Y3, Z1, Z2, and Z3 are independently selected from the group consisting of N and CR7, and wherein R7 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl; each m is independently an integer from 0 to 4; each t is independently an integer from 0 to 6; each R5, R6, R8, R9 and R10 is independently selected from the groupA · US 2006/0293328 A1 · claim 37
An empty cell means only that no passage was reproduced there.
The presently disclosed subject matter relates to methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues, processes for synthesizing novel dicationic terphenyl compounds and their aza analogues, and the novel dicationic terphenyl compounds and their aza analogues themselves.A · US 2006/0293328 A1 · ¶ 2
Thus, there continues to be a need for improvement in the art for additional compounds having desirable antimicrobial activity, whether against the representative pathogens referenced above or against other pathogens.A · US 2006/0293328 A1 · ¶ 60
This invention pertains to the field of anti-cancer compounds and, in particular, to the use of therapeutically active 2,4,5-trisubstituted imidazole compounds in the treatment of cancer.B · US 10,080,739 B2 · ¶ 2
The research in this field is therefore mainly directed to the synthesis of anticancer agents which would possess high antineoplastic activity, low systemic toxicity and low mutagenicity on normal cells.B · US 10,080,739 B2 · ¶ 4
patent.fyi, US 2026/0355169 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355169/, SHA-256 a878ddb46828e9c0540f2ec26ac6130577f8a897124d45c33638bb27763d0b74